Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
EIKN
Eikon Therapeutics, Inc.
CAPPED RATING
Eikon Therapeutics, Inc. (EIKN) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D-).
Quantitative Factor Evaluation • Updated
Overall Rating
1.8
/ 5.0
D+
Value
C+
Factor Score
2.5
/ 5.0
Growth
D+
Factor Score
1.8
/ 5.0
Profitability
D-
Factor Score
0.8
/ 5.0
Momentum
D
Factor Score
1.4
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-0.9
EV / EBITDA
-0.2
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-41.2%
Price Return 12M
-59.1%
Catalyst Signal
0.00
Market Cap
$332.0M
TTM Revenue
N/A
Price / Sales
N/A
ROE
N/A
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.5) | D+ (1.8) | D- (0.8) | D (1.4) | C+ (2.6) | D+ (1.8) |
| 2026-11-04 | C+ (2.5) | D+ (1.7) | D- (0.8) | D+ (1.5) | C+ (2.7) | D+ (1.8) |
| 2026-10-28 | C+ (2.5) | D+ (1.7) | D- (0.8) | D+ (1.7) | C+ (2.7) | C- (1.9) |
| 2026-10-21 | C+ (2.5) | D+ (1.7) | D- (0.8) | C- (1.9) | C+ (2.6) | C- (1.9) |
| 2026-10-14 | C+ (2.5) | D+ (1.8) | D- (0.8) | C- (1.9) | C+ (2.6) | C- (1.9) |
Page
1
of
4